elisidepsin

Drug Overview

Elisidepsin is an innovative, investigational cancer treatment derived from a marine organism. It is a synthetic version of a compound found in a sea slug. This medication is considered a Targeted Therapy and a “Smart Drug” because it attacks the structure of cancer cells in a very specific way, different from traditional chemotherapy.

• Generic Name: Elisidepsin (also known as PM02734 or Irvalec®)
• US Brand Names: None (Currently an Investigational Drug)
• Drug Class: Marine-derived synthetic cyclodepsipeptide; Marine-derived antitumor agent
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational. As of 2026, elisidepsin is not yet FDA-approved and is only available through clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Elisidepsin works as a Targeted Therapy by focusing on the outer boundary of the cancer cell the plasma membrane. Unlike many other treatments that must go deep inside the cell to work, elisidepsin acts like a “gatekeeper” that destroys the cell from the outside.

At the molecular level, its mechanism is highly specialized:

1. Targeting Lipid Rafts: The drug identifies and binds to specific fatty molecules (lipids) and proteins located in “lipid rafts” on the cancer cell’s surface. These rafts are critical communication hubs for the cell.
2. Membrane Insertion: Once it binds to these areas, elisidepsin inserts itself directly into the fatty layer of the cell membrane.
3. Physical Disruption: By wedging into the membrane, it creates physical instability. This leads to the formation of pores or “holes” in the cell’s protective wall.
4. Necrotic Cell Death: Because the membrane is broken, the cell can no longer control what enters or leaves. This causes the cell to swell and burst (a process called necrosis), leading to rapid cell death.
5. Signaling Blockade: In addition to physical destruction, elisidepsin blocks important survival signals, such as the Akt/mTOR pathway. By shutting down these chemical signals, the drug prevents the cancer cell from repairing itself or growing further.

FDA Approved Clinical Indications

Currently, there are no FDA-approved indications for elisidepsin. It is strictly used in research settings.

Oncological uses (Investigational):

• Advanced Solid Tumors: Studied in patients with cancers that have not responded to standard therapy.
• Non-Small Cell Lung Cancer (NSCLC): Investigated for specific genetic types of lung cancer.
• Gastrointestinal Cancers: Evaluated for cancers of the esophagus, stomach, and colon.
• Breast Cancer: Studied in combination with other targeted therapies.

Non-oncological uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Because elisidepsin is an investigational drug, the dosage is determined by the specific clinical trial protocol. It is administered as an infusion into a vein.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: Patients with liver issues may require a lower dose, as elisidepsin can cause temporary spikes in liver enzymes.
• Renal (Kidney) Insufficiency: Specific adjustments for kidney disease are still being determined in ongoing Phase I/II trials.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) has focused on how elisidepsin performs in patients who have already tried many other treatments.

• Disease Stabilization: In Phase I and II trials for advanced solid tumors, approximately 25% to 30% of patients experienced “Stable Disease,” meaning the cancer stopped growing for a significant period.
• Gastrointestinal Response: In studies focusing on esophageal and gastric cancers, elisidepsin showed potential when combined with other targeted drugs (like Erlotinib), showing a better response than when used alone.
• Survival Data: While long-term survival rates are still being calculated in Phase III trials, early data suggests that elisidepsin provides an alternative for patients whose tumors have become resistant to standard chemotherapy.

Safety Profile and Side Effects

The safety of elisidepsin is monitored closely in hospitals. It has a unique side effect profile compared to traditional “hair-loss” chemotherapy.

Black Box Warning: None. (As an investigational drug, it has not yet been assigned a formal Black Box Warning).

Common Side Effects (>10%):

• Pruritus (Itching): A very common reaction, often felt during the infusion.
• Fatigue: General feeling of tiredness or weakness.
• Nausea and Vomiting: Usually mild and manageable with medication.
• Infusion Site Reactions: Redness or discomfort where the IV is placed.

Serious Adverse Events:

• Hepatotoxicity: A sudden, temporary increase in liver enzymes (transaminases). This is the most common reason for pausing treatment.
• Hypersensitivity: Severe allergic reactions can occur, requiring immediate medical attention.

Management Strategies:

• Pre-medication: Doctors often give antihistamines before the infusion to prevent itching and allergic reactions.
• Liver Monitoring: Frequent blood tests are required to ensure the liver is processing the drug safely.

Research Areas

Current research into elisidepsin is looking at how it can be combined with Immunotherapy. Scientists believe that because elisidepsin “bursts” cancer cells, it might release tumor markers that help the immune system recognize and attack the remaining cancer. There is also ongoing research into how marine-derived drugs like this can target Cancer Stem Cells, which are often responsible for cancer returning after treatment.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

• Comprehensive Liver Function Tests (LFTs): To check baseline liver health.
• Baseline Blood Counts: To ensure the patient is strong enough for treatment.

Precautions during treatment:

• Avoid Alcohol: Alcohol can put extra stress on the liver during treatment.
• Skin Care: Use gentle, alcohol-free moisturizers to help with any drug-related itching.

“Do’s and Don’ts” list:

• DO report any yellowing of the skin or eyes (jaundice) to your doctor immediately.
• DO drink plenty of water on the day of your infusion.
• DON’T skip scheduled blood tests, as these are vital for checking your liver health.
• DON’T start any new herbal supplements without asking your oncologist, as they may interact with the drug.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Elisidepsin is an investigational drug and is only available through clinical trials. Always consult with a qualified healthcare professional regarding your diagnosis and treatment options. If you have a medical emergency, contact your local emergency services immediately.